A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention

Phase 2

Terminated

Conditions: Migraine

Interventions: Drug: BHV-3500 (zavegepant)
Drug: Placebo

Registration Number: NCT04804033

Lead Sponsor: Pfizer

Brief Summary: The purpose of this is study is to compare the efficacy of BHV-3500 (zavegepant) to placebo as a preventive treatment for migraine, as measured by the reduction in the number of migraine days per month.

Detailed Description: Not available

Recruitment & Eligibility

Status: TERMINATED

Sex: All

Target Recruitment: 1753

Inclusion Criteria

Subject has at least 1 year history of migraine (with or without aura) consistent with a diagnosis according to the International Classification of

Headache Disorders, 3rd Edition, including the following:

Age of onset of migraines prior to 50 years of age
Migraine attacks, on average, lasting 4 - 72 hours if untreated
Per subject report, at least 15 headache days per month, at lest 8 migraine days per month, and at least 1 headache-free day per month within the last 3 months prior to the Screening Visit
Eight or more migraine days during the Observation Period
15 or more headache days during the Observation Period
One or more non-headache days during the Observation Period
Ability to distinguish migraine attacks from tension/cluster headaches
Subjects on prophylactic migraine medication are permitted to remain on 1 medication with possible migraine-prophylactic effects if the dose has been stable for at least 3 months prior to the Screening Visit, and the dose is not expected to change during the course of the study.

Exclusion Criteria

Subject with a history of HIV disease
Subject history with current evidence of uncontrolled, unstable or recently diagnosed cardiovascular disease, such as ischemic heart disease, coronary artery vasospasm, and cerebral ischemia. Subjects with Myocardial Infarction (MI), Acute Coronary Syndrome (ACS), Percutaneous Coronary Intervention (PCI), cardiac surgery, stroke or transient ischemic attack (TIA) during the 6 months prior to screening
Uncontrolled hypertension (high blood pressure), or uncontrolled diabetes (however subjects can be included who have stable hypertension and/or diabetes for at least 3 months prior to screening).
Subjects with major depressive episode or anxiety disorder which require more than 1 daily medication for each disorder or subjects with a major depressive episode within the last 12 months. Medications to treat major depressive disorder or an anxiety disorder must have been at a stable dose for at least 3 months prior to the Screening Visit.
Subjects with active chronic pain syndromes, other pain syndromes (including trigeminal neuralgia), psychiatric conditions, dementia, or significant neurological disorders (other than migraine) that, in the Investigator's opinion interfere with study assessments of safety or efficacy.
Subject has a history of gastric, or small intestinal surgery (including Gastric Bypass, Gastric Banding, Gastric Sleeve, Gastric Balloon, etc.), or has disease or condition (e.g. chronic pancreatitis, ulcerative colitis, etc.) that causes malabsorption.
Body mass index > 33 kg/m2
History of gallstones or cholecystectomy.
The subject has a history or current evidence of any unstable medical conditions (e.g., history of congenital heart disease or arrhythmia, known or suspected infection, hepatitis B or C, or cancer) that, in the investigator's opinion, would expose them to undue risk of a significant adverse event (AE) or interfere with assessments of safety or efficacy during the course of the trial

Study & Design

Study Type: INTERVENTIONAL

Study Design: SEQUENTIAL

Arm && Interventions

Group	Intervention	Description
BHV-3500 200mg	BHV-3500 (zavegepant)	Zavegepant 200mg oral soft gel capsule.
Placebo 200mg	Placebo	Matching placebo 200mg oral soft gel capsule.
BHV-3500 100mg	BHV-3500 (zavegepant)	Zavegepant 100mg oral soft gel capsule.
Placebo 100mg	Placebo	Matching placebo 100mg oral soft gel capsule.

Primary Outcome Measures

Name	Time	Method
Mean Change From Observation Phase (OP) in the Number of Migraine Days Per Month Over Entire DBT Phase (Weeks 1 to 12)	Observation Phase: 28 days prior to randomization and baseline; Entire DBT Phase: 12 weeks (Week 1 through 12)	A migraine day was defined as any calendar day in which participant experienced a qualified migraine headache (onset, continuation or recurrence of migraine headache). A qualified migraine headache was defined as migraine with or without aura, lasting for greater than or equal to (\>=) 30 minutes, and met at least one of the following criteria (A and/or B): A. \>=2 of the following pain features: a. Unilateral location, b. Pulsating quality (throbbing), c. Moderate or severe pain intensity, d. Aggravation by or causing avoidance of routine physical activity (e.g. walking or climbing stairs) B. \>= 1 of following associated symptoms: a. Nausea and/or vomiting b. Photophobia and phonophobia. The number of migraine days per month were prorated to 28 days and derived as follows: 28\*(total number of migraine days through Month 3\[Weeks 1 to 12\] in on-DBT efficacy analysis period)/ (total number of eDiary efficacy data days through Month 3\[Weeks 1 to 12\] in the on-DBT efficacy analysis period).

Secondary Outcome Measures

Name	Time	Method
Number of Participants With Hepatic-related AEs Leading to Study Drug Discontinuation: OLE Phase	OLE: Over 52 weeks of treatment	An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment.
Percentage of Participants With >= 50 % Reduction in Number of Moderate to Severe Migraine Days Per Month Over Entire DBT Phase (Weeks 1 to 12)	Entire DBT Phase: 12 weeks (Week 1 through 12)	A migraine day was defined as any calendar day in which participant experienced a qualified migraine headache (onset, continuation or recurrence of the migraine headache). A qualified migraine headache was defined as migraine with or without aura, lasting for greater than or equal to (\>=) 30 minutes, and met at least one of following criteria (A and/or B): A. \>=2 of following pain features: a. Unilateral location, b. Pulsating quality (throbbing), c. Moderate or severe pain intensity, d. Aggravation by or causing avoidance of routine physical activity (e.g. walking or climbing stairs) B. \>= 1 of the following associated symptoms: a. Nausea and/or vomiting b. Photophobia and phonophobia. The number of migraine days per month were prorated to 28 days and derived as follows: 28\*(total number of migraine days through Month 3\[Weeks 1 to 12\] in the on-DBT efficacy analysis period)/ (total number of eDiary efficacy data days through Month 3\[Weeks 1 to 12\] in on-DBT efficacy analysis period).
Mean Change From Observation Phase in the Number of Migraine Days Per Month in the Last 4 Weeks (Weeks 9 to 12) of DBT Phase	Observation Phase: 28 days prior to randomization and baseline; DBT Phase: last 4 weeks (Week 9 through 12)	A migraine day was defined as any calendar day in which the participant experienced a qualified migraine headache (onset, continuation or recurrence of the migraine headache). A qualified migraine headache was defined as a migraine with or without aura, lasting for greater than or equal to (\>=) 30 minutes, and met at least one of the following criteria (A and/or B): A.\>=2 of the following pain features: a. Unilateral location, b. Pulsating quality (throbbing), c. Moderate or severe pain intensity, d. Aggravation by or causing avoidance of routine physical activity (e.g. walking or climbing stairs) B. \>= 1 of the following associated symptoms: a. Nausea and/or vomiting b. Photophobia and phonophobia. The number of migraine days per month were prorated to 28 days and derived for month (i.e., 4-week interval) in on-DBT efficacy analysis period as follows: 28\* (total number of migraine days in the month\[Week 9 to 12\])/(total number of eDiary efficacy data days in the month\[Week 9 to 12\]).
Mean Change From Observation Phase in the Number of Migraine Days Per Month in the First 4 Weeks (Weeks 1 to 4) of DBT Phase	Observation Phase: 28 days prior to randomization and baseline; DBT Phase: first 4 weeks (Week 1 through 4)	A migraine day was defined as any calendar day in which participant experienced a qualified migraine headache (onset, continuation or recurrence of the migraine headache). A qualified migraine headache was defined as a migraine with or without aura, lasting for greater than or equal to (\>=) 30 minutes, and met at least one of the following criteria (A and/or B): A. \>=2 of the following pain features: a. Unilateral location, b. Pulsating quality (throbbing), c. Moderate or severe pain intensity, d. Aggravation by or causing avoidance of routine physical activity (e.g. walking or climbing stairs) B. \>= 1 of the following associated symptoms: a. Nausea and/or vomiting b. Photophobia and phonophobia. The number of migraine days per month were prorated to 28 days and derived for month (i.e., 4-week interval) in the on-DBT efficacy analysis period as follows: 28\* (total number of migraine days in the month\[Week 1 to 4\])/ (total number of eDiary efficacy data days in the month\[Week 1 to 4\]).
Mean Number of Acute Migraine -Specific Medication Days Per Month Over Entire DBT Phase (Weeks 1 to 12)	Entire DBT Phase: 12 weeks (Week 1 through 12)	Acute migraine (AM)-specific medication day was defined as any calendar day on which the participant took an acute migraine-specific medication during aura or to treat a headache. Acute migraine-specific medications were triptans and ergotamine. The number of acute migraine-specific medication days per month were prorated to 28 days and derived as follows: 28 \* (total number of acute migraine-specific medication days through Month 3 \[Week 1 to 12\] in the on-DBT efficacy analysis period)/ (total number of eDiary efficacy data days through Month 3 \[Week 1 to 12\] in the on-DBT efficacy analysis period).
Mean Change From Baseline in the Migraine-specific Quality of Life Questionnaire (MSQ) v 2.1 Restrictive Role Function Domain Score at Week 12	DBT Phase: Baseline (before dose on Day 1), Week 12	MSQ v 2.1 is 14-item questionnaire that assessed impact of treatment on participant-reported quality of life across 3 domains: role function-restrictive, preventive, and emotional function. Restrictive role function domain consists of 7 items that describe how migraine limits one's daily social, work-related activities. Participants respond to items using a 6-point scale ranging from 1 (none of the time) to 6 (all of the time), which are assigned scores of 1 to 6, respectively. Response from each item of restrictive role function domain were added providing a possible raw score range of 7 (no impairment) to 42 (maximum impairment). Raw score range of restrictive role function domain was then transformed to a 0 (no impairment) to 100 (maximum impairment), higher scores = higher impairment.
Mean Change From Baseline in the Migraine Disability Assessment (MIDAS) Total Score at Week 12	DBT Phase: Baseline (before dose on Day 1), Week 12	MIDAS is a retrospective, participant-reported, 5-item questionnaire that measured headache related disability as lost days due to headache from paid work or school, household work and non-work activities over past 3-months. The total score is calculated as the sum of item scores to all 5 questions on a scale of 0 (no disability) to 90 (maximum disability) resulting into overall possible MIDAS total score (range from 0 (no disability) to 450 (maximum disability). Higher scores = more severe disability.
Number of Participants With Moderate or Severe Adverse Events (AEs): DBT Phase	DBT Phase: During 12 weeks of treatment	AEs: new untoward medical occurrence or worsening of a pre-existing medical condition in participant or clinical investigation participant administered investigational product that does not necessarily have a causal relationship with treatment. AEs included both SAEs and all non-SAEs. Severity: Moderate=Alleviated with additional specific therapeutic intervention, interfered with activities of daily living, causing discomfort, but possessed no significant or permanent risk of harm. Severe= Interrupted activities of daily living significantly affected clinical status or required intensive therapeutic intervention.
Number of Participants With Serious Adverse Events (SAEs): DBT Phase	DBT Phase: During 12 weeks of treatment	AEs: new untoward medical occurrence or worsening of a pre-existing medical condition in participant or clinical investigation participant administered investigational product that does not necessarily have a causal relationship with treatment. SAE was defined as any event that met any of the following criteria: death; life-threatening; inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect in the offspring of a participant; other important medical events that may not have resulted in death, be life-threatening, or required hospitalization, based upon appropriate medical judgment, they may have jeopardized the participant and may have required medical or surgical intervention.
Number of Participants With AEs Leading to Study Drug Discontinuation: DBT Phase	DBT Phase: During 12 weeks of treatment	An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment.
Number of Participants With Grade 3 to 4 Laboratory Test Abnormalities: DBT Phase	DBT: During 12 weeks of treatment	Laboratory tests included eosinophils, hemoglobin, leukocytes, lymphocytes, neutrophils, platelets; albumin, alkaline phosphatase, alanine aminotransferase (ALT), aspartate aminotransferase (AST), bicarbonate, bilirubin, calcium, cholesterol, potassium, sodium, triglycerides, uric acid, urinalysis, urine protein, creatine kinase (CK), creatinine, glomerular filtration rate (GFR), glucose, glucose fasting, lactate dehydrogenase, low density lipoprotein (LDL) Cholesterol, LDL Cholesterol. Number of participants with grade 3 to 4 laboratory test abnormalities were evaluated in this outcome measure. Only rows which included at least 1 participant in any reporting group with grade 3 to 4 abnormality were reported in this outcome measure. As per Common Terminology Criteria for Adverse Events (CTCAE version 5.0) Grade 3= severe and Grade 4= life-threatening or disabling.
Number of Participants With Moderate or Severe AEs: OLE Phase	OLE: During 52 weeks of treatment	AEs: new untoward medical occurrence or worsening of a pre-existing medical condition in participant or clinical investigation participant administered investigational product that does not necessarily have a causal relationship with treatment. AEs included both SAEs and all non-SAEs. Severity: Moderate=Alleviated with additional specific therapeutic intervention, interfered with activities of daily living, causing discomfort, but possessed no significant or permanent risk of harm. Severe= Interrupted activities of daily living significantly affected clinical status or required intensive therapeutic intervention.
Number of Participants With SAEs: OLE Phase	OLE: During 52 weeks of treatment	AEs: new untoward medical occurrence or worsening of a pre-existing medical condition in participant or clinical investigation participant administered investigational product that does not necessarily have a causal relationship with treatment. SAE was defined as any event that met any of the following criteria: death; life-threatening; inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect in the offspring of a participant; other important medical events that may not have resulted in death, be life-threatening, or required hospitalization, based upon appropriate medical judgment, they may have jeopardized the participant and may have required medical or surgical intervention.
Number of Participants With AEs Leading to Study Drug Discontinuation: OLE Phase	OLE: During 52 weeks of treatment	An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment.
Number of Participants With Grade 3 to 4 Laboratory Test Abnormalities: OLE Phase	OLE: During 52 weeks of treatment	Laboratory tests included eosinophils, hemoglobin, leukocytes, lymphocytes, neutrophils, platelets; albumin, alkaline phosphatase, alanine aminotransferase (ALT), aspartate aminotransferase (AST), bicarbonate, bilirubin, calcium, cholesterol, potassium, sodium, triglycerides, uric acid, urinalysis, urine protein, creatine kinase (CK), creatinine, glomerular filtration rate (GFR), glucose, glucose fasting, lactate dehydrogenase, low density lipoprotein (LDL) Cholesterol, LDL Cholesterol. Number of participants with grade 3 to 4 laboratory test abnormalities were evaluated in this outcome measure. Only rows which included at least 1 participant in any reporting group with grade 3 to 4 abnormality were reported in this outcome measure. As per Common Terminology Criteria for Adverse Events (CTCAE version 5.0) Grade 3= severe and Grade 4= life-threatening or disabling.
Percentage of Participants With AST or ALT Elevations >3 * ULN With Total Bilirubin > 2 * ULN: DBT Phase	DBT: Over 12 weeks of treatment	Elevations of AST or alanine aminotransferase (ALT) \> 3 \upper limit of normal (ULN) concurrent with total bilirubin (TBL) \> 2 \ULN (elevations on the same laboratory collection date) were included.
Percentage of Participants With AST or ALT Elevations >3 * ULN With Total Bilirubin > 2 * ULN: OLE Phase	OLE: Over 52 weeks of treatment	Elevations of AST or ALT \> 3 \* ULN concurrent with TBL \> 2 \*ULN were defined as elevations on the same collection date.
Number of Participants With Hepatic-related AEs by Intensity: DBT Phase	DBT Phase: During 12 weeks of treatment	An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. AEs by intensity: Mild: Transient and may require only minimal treatment or therapeutic intervention. Event did not interfere with activities of daily living. Moderate: Alleviated with additional specific therapeutic intervention. Event interfered with activities of daily living, causing discomfort, but possessed no significant or permanent risk of harm. Severe: Interrupted activities of daily living significantly affected clinical status or required intensive therapeutic intervention.
Number of Participants With Hepatic-related AEs Leading to Study Drug Discontinuation: DBT Phase	DBT Phase: During 12 weeks of treatment	An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment.
Number of Participants With Hepatic-related AEs by Intensity: OLE Phase	OLE: Over 52 weeks of treatment	An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. AEs by intensity: Mild: Transient and may require only minimal treatment or therapeutic intervention. Event did not interfere with activities of daily living. Moderate: Alleviated with additional specific therapeutic intervention. Event interfered with activities of daily living, causing discomfort, but possessed no significant or permanent risk of harm. Severe: Interrupted activities of daily living significantly affected clinical status or required intensive therapeutic intervention.

Trial Locations

Locations (102): Clinical Research Philadelphia, LLC
🇺🇸
Philadelphia, Pennsylvania, United States
Meridian Clinical Research, LLC
🇺🇸
Norfolk, Virginia, United States
Clinical Investigation Specialists, Inc
🇺🇸
Gurnee, Illinois, United States
MediSphere Medical Research Center, LLC
🇺🇸
Evansville, Indiana, United States
Accellacare
🇺🇸
Wilmington, North Carolina, United States
Tucson Neuroscience Research
🇺🇸
Tucson, Arizona, United States
Alliance for Multispecialty Research, LLC
🇺🇸
Newton, Kansas, United States
Romedica LLC
🇺🇸
Rochester, Michigan, United States
StudyMetrix Research
🇺🇸
Saint Peters, Missouri, United States
North Suffolk Neurology, PC
🇺🇸
Port Jefferson Station, New York, United States
Kansas Institute of Research
🇺🇸
Overland Park, Kansas, United States
Hometown Urgent Care and Research
🇺🇸
Dayton, Ohio, United States
Reading Hospital Clinical Trials Office
🇺🇸
West Reading, Pennsylvania, United States
Collevtive Medical Research
🇺🇸
Overland Park, Kansas, United States
MedVadis Research Corporation
🇺🇸
Waltham, Massachusetts, United States
Preferred Primary Care Physicians
🇺🇸
Uniontown, Pennsylvania, United States
M3 Wake Research, Inc.
🇺🇸
Raleigh, North Carolina, United States
Headache Wellness Center
🇺🇸
Greensboro, North Carolina, United States
Coastal Carolina Research Center
🇺🇸
North Charleston, South Carolina, United States
Neuro-Behavioral Clinical Research, Inc.
🇺🇸
North Canton, Ohio, United States
Clinical Investigation Specialists, Inc.
🇺🇸
Gurnee, Illinois, United States
Dent Neurosciences Research Center, Inc.
🇺🇸
Amherst, New York, United States
North Texas Institute of Neurology and Headache - NextStage Clinical Research
🇺🇸
Frisco, Texas, United States
Radiance Clinical Research
🇺🇸
Lampasas, Texas, United States
Red Star Research. LLC
🇺🇸
Lake Jackson, Texas, United States
DM Clinical Research
🇺🇸
Tomball, Texas, United States
MediSphere Medical Research Center, LLC.
🇺🇸
Evansville, Indiana, United States
Tower Health Medical Group - Neurology
🇺🇸
West Reading, Pennsylvania, United States
Internal Medicine and Pediatric Associates of Bristol, PC
🇺🇸
Bristol, Tennessee, United States
Crescent City Headache and Neurology Center
🇺🇸
Chalmette, Louisiana, United States
Community Clinical Research Network Inc
🇺🇸
Marlborough, Massachusetts, United States
Carolina Research Center, Inc.
🇺🇸
Shelby, North Carolina, United States
Neurology Center of New England P.C.
🇺🇸
Foxboro, Massachusetts, United States
Accellacare (Administrative Only)
🇺🇸
Bristol, Tennessee, United States
Central New York Clinical Research
🇺🇸
Manlius, New York, United States
WellNow Urgent Care and Research
🇺🇸
Troy, Ohio, United States
New York Neurology Associates
🇺🇸
New York, New York, United States
FMC Science
🇺🇸
Lampasas, Texas, United States
Clinvest Research, LLC
🇺🇸
Springfield, Missouri, United States
Fieve Clinical Research, Inc
🇺🇸
New York, New York, United States
FutureSearch Trials of Dallas, LP
🇺🇸
Dallas, Texas, United States
Charlottesville Medical Research Center, LLC
🇺🇸
Charlottesville, Virginia, United States
KCA Neurology, PLLC
🇺🇸
Franklin, Tennessee, United States
North Texas Institute of Neurology and Headache
🇺🇸
Frisco, Texas, United States
WR-ClinSearch, LLC
🇺🇸
Chattanooga, Tennessee, United States
Northwest Clinical Research Center
🇺🇸
Bellevue, Washington, United States
Wellnow Urgent Care and Research
🇺🇸
Columbus, Ohio, United States
Preferred Primary Care Physicians, Inc.
🇺🇸
Pittsburgh, Pennsylvania, United States
Seattle Clinical Research Center
🇺🇸
Seattle, Washington, United States
Boston Clinical Trials
🇺🇸
Boston, Massachusetts, United States
Brainstorm Research
🇺🇸
Miami, Florida, United States
Texas Center for Drug Development, Inc.
🇺🇸
Houston, Texas, United States
Artemis Institute for Clinical Research
🇺🇸
San Diego, California, United States
Excel Clinical research
🇺🇸
Las Vegas, Nevada, United States
Wr-Crcn, Llc
🇺🇸
Las Vegas, Nevada, United States
CTI Clinical Research Center
🇺🇸
Cincinnati, Ohio, United States
Wellnow Urgent Care
🇺🇸
Cincinnati, Ohio, United States
Hightower Clinical
🇺🇸
Oklahoma City, Oklahoma, United States
Summit Headlands LLC, dba Summit Research
🇺🇸
Portland, Oregon, United States
Wasatch Clinical Research , LLC(Administrative Location)
🇺🇸
Salt Lake City, Utah, United States
Upstate Clinical Research Associates, LLC
🇺🇸
Williamsville, New York, United States
Xenoscience, Inc
🇺🇸
Phoenix, Arizona, United States
Wr-Pri, Llc
🇺🇸
Newport Beach, California, United States
Hope Clinical Research
🇺🇸
Canoga Park, California, United States
eStudySite
🇺🇸
La Mesa, California, United States
Axiom Research, Llc
🇺🇸
Colton, California, United States
Synergy San Diego
🇺🇸
Lemon Grove, California, United States
Collaborative Neuroscience Research, LLC.
🇺🇸
Long Beach, California, United States
Clinical Research Institute
🇺🇸
Los Angeles, California, United States
California Neuroscience Research Medical Group, inc.
🇺🇸
Sherman Oaks, California, United States
CMR of Greater New Haven, LLC
🇺🇸
Hamden, Connecticut, United States
Ki Health Partners, LLc, dba New England Institute for Clinical Research
🇺🇸
Stamford, Connecticut, United States
Chase Medical Research, LLC
🇺🇸
Waterbury, Connecticut, United States
Neurology Offices of South Florida
🇺🇸
Boca Raton, Florida, United States
Accel Research Sites Network - Edgewater Clinical Research Unit
🇺🇸
Edgewater, Florida, United States
Complete Health Research
🇺🇸
Ormond Beach, Florida, United States
Clinical Neuroscience Solutions, Inc.
🇺🇸
Memphis, Tennessee, United States
Multi-Specialty Research Associates, Inc.
🇺🇸
Lake City, Florida, United States
AppleMed Research Group, LLC
🇺🇸
Miami, Florida, United States
Ideal Clinical Research
🇺🇸
Pembroke Pines, Florida, United States
The Neurology Research Group
🇺🇸
Miami, Florida, United States
Clinical Research Center of Florida
🇺🇸
Pompano Beach, Florida, United States
Accel Research Sites Network - St. Petersburg Clinical Research Unit
🇺🇸
Saint Petersburg, Florida, United States
Clin-Med Research & Development LLC
🇺🇸
South Miami, Florida, United States
iResearch Atlanta LLC
🇺🇸
Decatur, Georgia, United States
CenExel iResearch, LLC
🇺🇸
Decatur, Georgia, United States
Cedar Crosse Research Center
🇺🇸
Chicago, Illinois, United States
Health Research of Hampton Roads, Inc.
🇺🇸
Newport News, Virginia, United States
Seattle Women's: Health, Research, Gynecology
🇺🇸
Seattle, Washington, United States
ForCare Clinical Research
🇺🇸
Tampa, Florida, United States
JSV Clinical Research Study Inc
🇺🇸
Tampa, Florida, United States
Michigan Head Pain & Neurological Institute
🇺🇸
Ann Arbor, Michigan, United States
FutureSearch Trials of Neurology
🇺🇸
Austin, Texas, United States
Alliance for Multispecialty Reseach, LLC
🇺🇸
Kansas City, Missouri, United States
L-MARC Research Center
🇺🇸
Louisville, Kentucky, United States
Alliance for Multispecialty Research, LLC.
🇺🇸
New Orleans, Louisiana, United States
Sarkis Clinical Trials
🇺🇸
Gainesville, Florida, United States
DelRicht Research
🇺🇸
New Orleans, Louisiana, United States
The Research Group of Lexington, Llc.
🇺🇸
Lexington, Kentucky, United States
The Research Group of Lexington, Llc
🇺🇸
Lexington, Kentucky, United States
Albuquerque Clinical Trials, Inc.
🇺🇸
Albuquerque, New Mexico, United States
Montefiore Medical Center
🇺🇸
Bronx, New York, United States